168 related articles for article (PubMed ID: 37687086)
1. Deacetylated Sialic Acid Sensitizes Lung and Colon Cancers to Novel Cucurbitacin-Inspired Estrone Epidermal Growth Factor Receptor (EGFR) Inhibitor Analogs.
Anim MT; Tuffour I; Willis R; Schell M; Ostlund T; Mahnashi MH; Halaweish F; Willand-Charnley R
Molecules; 2023 Aug; 28(17):. PubMed ID: 37687086
[TBL] [Abstract][Full Text] [Related]
2. Early
Tuffour I; Amuzu S; Bayoumi H; Surtaj I; Parrish C; Willand-Charnley R
Front Oncol; 2023; 13():1145333. PubMed ID: 37377914
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological study of hybrid drug candidates of nitric oxide releasing cucurbitacin-inspired estrone analogs for treatment of hepatocellular carcinoma.
Abou-Salim MA; Shaaban MA; Abd El Hameid MK; Elshaier YAMM; Halaweish F
Bioorg Chem; 2019 Apr; 85():515-533. PubMed ID: 30807895
[TBL] [Abstract][Full Text] [Related]
4. Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway.
Grabenstein S; Barnard KN; Anim M; Armoo A; Weichert WS; Bertozzi CR; Parrish CR; Willand-Charnley R
Glycobiology; 2021 Nov; 31(10):1279-1294. PubMed ID: 34192335
[TBL] [Abstract][Full Text] [Related]
5. Expression of 9-
Barnard KN; Wasik BR; LaClair JR; Buchholz DW; Weichert WS; Alford-Lawrence BK; Aguilar HC; Parrish CR
mBio; 2019 Dec; 10(6):. PubMed ID: 31796537
[TBL] [Abstract][Full Text] [Related]
6. Estrone analogs as potential inhibitors targeting EGFR-MAPK pathway in non-small-cell lung cancer.
Acheampong F; Ostlund T; Mahnashi M; Halaweish F
Chem Biol Drug Des; 2023 Jun; 101(6):1356-1366. PubMed ID: 36775996
[TBL] [Abstract][Full Text] [Related]
7. Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells.
Park JJ; Yi JY; Jin YB; Lee YJ; Lee JS; Lee YS; Ko YG; Lee M
Biochem Pharmacol; 2012 Apr; 83(7):849-57. PubMed ID: 22266356
[TBL] [Abstract][Full Text] [Related]
8. Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells.
Fei SJ; Zhang XC; Dong S; Cheng H; Zhang YF; Huang L; Zhou HY; Xie Z; Chen ZH; Wu YL
PLoS One; 2013; 8(7):e69104. PubMed ID: 23874880
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors.
Liu C; Wang Z; Liu Q; Wu G; Chu C; Li L; An L; Duan S
Clin Transl Oncol; 2022 Oct; 24(10):1975-1985. PubMed ID: 35666454
[TBL] [Abstract][Full Text] [Related]
10. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
12. Cucurbitacins inspired organic synthesis: Potential dual inhibitors targeting EGFR - MAPK pathway.
Mahnashi M; Elgazwi SM; Ahmed MS; Halaweish FT
Eur J Med Chem; 2019 Jul; 173():294-304. PubMed ID: 31022583
[TBL] [Abstract][Full Text] [Related]
13. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
14. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
[TBL] [Abstract][Full Text] [Related]
15. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
16. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.
Song JY; Kim CS; Lee JH; Jang SJ; Lee SW; Hwang JJ; Lim C; Lee G; Seo J; Cho SY; Choi J
Invest New Drugs; 2013 Dec; 31(6):1458-65. PubMed ID: 24068620
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer.
Liu D; Cao Z; Xu W; Lin G; Zhou X; Ding X; Wang N; Wu C; Su B
Biomed Pharmacother; 2019 Sep; 117():109185. PubMed ID: 31387179
[TBL] [Abstract][Full Text] [Related]
19. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
20. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]